venBio Global Strategic Fund IV, L.P. - 06 Aug 2026 Form 4 Insider Report for Attovia Therapeutics, Inc. (ATTO)

Reporting relationship: 10%+ Owner
Issuer ticker: ATTO
Reported as of: 06 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Aug 2026, 16:12:09 UTC
Prior SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: venBio Global Strategic Fund IV, L.P., by: venBio Global Strategic GP IV, LLC, its general partner, by: /s/ David Pezeshki, as attorney-in-fact

Key filing fact

venBio Global Strategic Fund IV, L.P. filed Form 4 for Attovia Therapeutics, Inc. (ATTO) on 10 Aug 2026.

Key facts

This page summarizes venBio Global Strategic Fund IV, L.P.'s Form 4 filing for Attovia Therapeutics, Inc. (ATTO).
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 10 Aug 2026, 16:12.

Change

Previous filing in this sequence was filed on 04 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001862109 Primary reporting owner

venBio Global Strategic Fund IV, L.P.

Relationship: 10%+ Owner
Address: 1700 OWENS STREET, SUITE 595, SAN FRANCISCO
Signature: venBio Global Strategic Fund IV, L.P., by: venBio Global Strategic GP IV, LLC, its general partner, by: /s/ David Pezeshki, as attorney-in-fact
Signature date: 10 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,311,870
Change %
Price
Shares after: 2,311,870
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +821,998
Change %: +36%
Price
Shares after: 3,133,868
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ATTO transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +665,147
Change %: +21%
Price
Shares after: 3,799,015
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ATTO transaction

Common Stock

Purchase

Transaction value
Shares: +382,352
Change %: +10%
Price: $17.00^*
Shares after: 4,181,367
Date: 06 Aug 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATTO transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -21,477,273
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,311,870
Exercise price
Footnotes: F1, F2

ATTO transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -7,636,362
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 821,998
Exercise price
Footnotes: F1, F2

ATTO transaction Derivative

Series C Preferred Stock

Conversion of derivative security

Transaction value
Shares: -6,179,219
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 06 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 665,147
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

venBio Global Strategic Fund IV, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.

Footnote F2

These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.